Abstract: The present disclosure provides for pharmaceutical compositions useful for treating autism spectrum disorder. The pharmaceutical compositions comprise particular THC:CBD ratios and terpene profiles, which have been demonstrated effective at treating cluster symptoms associated with autism spectrum disorder.
Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
Type:
Grant
Filed:
June 28, 2022
Date of Patent:
April 4, 2023
Assignee:
Tremeau Pharmaceuticals, Inc.
Inventors:
Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.
Type:
Grant
Filed:
February 16, 2022
Date of Patent:
February 28, 2023
Assignee:
SLAYBACK PHARMA LLC
Inventors:
Sushant Omprakash Dube, Suprit Dilip Saoji, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai, Girish G. Kore
Abstract: The present invention relates to non-hormonal compositions and methods for inducing a condition of aspermia, azoospermia, or severe oligozoospermia in the male subject such that these compositions and methods for administering the same may be used as male contraception. Embodiments of the present invention may comprise a composition comprising an alpha-1-adrenoreceptor antagonist, such as (R)-silodosin, for daily administration to a male subject. The compositions and related methods may further include pharmaceutically acceptable carriers. The present invention further includes formulations which allow for a delay such that delayed or missed dose(s) do not nullify the contraceptive effect of the treatment regimen. Such compositions and methods may also avoid the side effects associated with typical formulations of alpha-1-adrenoreceptor antagonists.
Type:
Grant
Filed:
December 30, 2020
Date of Patent:
February 21, 2023
Assignee:
PHARMAJOR INTERNATIONAL
Inventors:
Guillaume El Glaoui, Mehdi El Glaoui, Philippe Perrin, Stéphane Droupy, Véronique Agathon-Meriau
Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
Type:
Grant
Filed:
February 26, 2021
Date of Patent:
February 14, 2023
Assignee:
Tremeau Pharmaceuticals, Inc.
Inventors:
Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
Type:
Grant
Filed:
June 28, 2022
Date of Patent:
January 24, 2023
Assignee:
Tremeau Pharmaceuticals, Inc.
Inventors:
Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
Abstract: The present invention features a method of reducing tactile dysfunction or anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett Syndrome, or Fragile X syndrome by administering a GABAA agent having reduced blood brain barrier or by expressing a nucleic acid encoding an exogenous alpha or beta subunit of a GABAA receptor in dorsal root ganglion neurons in the subject using a vector.
Type:
Grant
Filed:
June 8, 2017
Date of Patent:
January 10, 2023
Assignee:
President and Fellows of Harvard College
Abstract: Disclosed are applications of spermidine or its pharmaceutically acceptable derivatives. The inventors performed calculation and analysis using software based on existing data relating to protein and small-molecule structures, and screened out compounds which can effectively interfere with the activity of PAWS and thus reduce SAICAR synthesis, thereby achieving the goal of treating or improving tumors. It is expected to produce better effect in the treatment or improvement of tumors.
Abstract: The present invention relates to a compound, in particular a meroterpenoid compound, or salt thereof, for use in the prevention and/or treatment of a neurological disorder in an individual. The compound of the invention can promote lactate secretion. A composition comprising the compound of the invention, and a food or food extract enriched with said compound or composition is also provided.
Type:
Grant
Filed:
September 13, 2018
Date of Patent:
November 29, 2022
Assignee:
Societe des Produits Nestle S.A.
Inventors:
Denis Marcel Barron, Yann Ratinaud, Jonathan Thevenet, Andreas Christian Wiederkehr
Abstract: Compounds and methods for modulating the activity of receptors are disclosed. Some of the compounds modulate the activity of glycine receptors. Certain embodiments of the compounds are useful for treatment of pain, treatment of opioid addiction, and/or reduction of side effects attributable to opioid use.
Type:
Grant
Filed:
July 13, 2018
Date of Patent:
November 1, 2022
Assignee:
University of Pittsburgh—Of the Commonwealth Sysetem of Higher Education
Abstract: Pharmaceuticals compositions comprising the 2S,4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R,4S ketoconazole enantiomer are useful to reduce cortisol synthesis and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.
Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.
Abstract: A first aspect of the invention relates to leucine, acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a migraine, or one or more symptoms associated therewith. A second aspect of the invention relates to a method of treating or preventing a migraine, or one or more symptoms associated therewith, in a subject, said method comprising administering to the subject a therapeutically or prophylactically effective amount of leucine, acetyl-leucine, or a pharmaceutically acceptable salt thereof.
Abstract: This TRPA1 activity inhibitor contains a compound represented by formula (I) wherein R1, R2, R3 and R4 each independently represent a hydrogen atom or a methyl group, and R5, R6, R7 and R8 each independently represent a hydrogen atom, a methyl group or —O—R9—OH (in the formula, R9 represents an alkylene group optionally having a substituent group), provided that at least one group of R5, R6, R7 and R8 is —O—R9—OH.
Type:
Grant
Filed:
March 13, 2018
Date of Patent:
October 11, 2022
Assignees:
MANDOM CORPORATION, TAKASAGO INTERNATIONAL CORPORATION
Inventors:
Masayuki Takaishi, Fumitaka Fujita, Hironori Shimizu, Shu Sakuyama, Kenya Ishida, Kenji Maruyama
Abstract: The present invention relates to 5-HT6 receptor antagonists for the treatment of Alzheimer's disease where the Alzheimer's disease patient carries one or two ApoE4 alleles comprising administering an effective dose of a 5-HT6 receptor antagonist to improve or augment the effect of an acetylcholinesterase inhibitor.
Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.
Type:
Grant
Filed:
January 13, 2021
Date of Patent:
October 11, 2022
Assignee:
Amarin Pharmaceuticals Ireland Limited
Inventors:
Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
Abstract: Methods and compositions that can be used to modulate the activity of furin in a subject are disclosed herein. In some embodiments, the methods include administering a pharmaceutical composition including a protease inhibitor. In some embodiments, the protease inhibitor inhibits furin activity by binding to the catalytic site, the allosteric site, or both.
Abstract: A topical composition includes a cannabinoid, a terpenoid, and a skin penetration system that includes dimethyl sulfoxide (DMSO) and at least one compatibilizer. The composition may be in the form of an emulsion that further contains water and at least one fatty component. The composition can be used to reduce or eliminate pain by topical application to an affected region of the body. The composition provides localized pain relief by providing a focused quantity of cannabinoid in the region of the pain instead of distributing the cannabinoid systemically and/or delivering it to the brain or central nervous system.
Abstract: The present invention relates to compositions comprising an antiemetic, particularly including 5-HT3 antagonist and/or NK-1 antagonist antiemetics, in combination with a choline esterase inhibitor such as an acetylcholine esterase inhibitor and/or a butyrylcholine esterase inhibitor, and methods of using the composition to provide improved protection of subjects at risk of organophosphorus poisoning, or, for the treatment, prevention, or alleviation/reduction of toxicity from an organophosphorus compound, by enabling the use of a highly protective daily dose of the choline esterase inhibitor without the typical adverse effects.